Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Assets: 2023-2024

Historic Current Assets for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $377.4 million.

  • Monte Rosa Therapeutics' Current Assets rose 59.95% to $401.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.8 million, marking a year-over-year increase of 59.95%. This contributed to the annual value of $377.4 million for FY2024, which is 59.79% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Current Assets is $377.4 million, which was up 59.79% from $236.2 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Current Assets high stood at $377.4 million for FY2024, and its period low was $236.2 million during FY2023.
  • Its 2-year average for Current Assets is $306.8 million, with a median of $306.8 million in 2023.
  • Data for Monte Rosa Therapeutics' Current Assets shows a peak YoY spiked of 59.79% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Current Assets (Yearly) stood at $236.2 million in 2023, then skyrocketed by 59.79% to $377.4 million in 2024.